top of page

研究業績

主たる原著論文

2023

  1. Tsunokake S, Iwabuchi E, Suzuki T, et al. SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast. Breast Cancer Res Treat. 2023 Oct;201(3):499-513. doi: 10.1007/s10549-023-07024-9.

  2. Freeha Khalid, Takagi K, Sato A, et al. Interleukin (IL)-17A in triple-negative breast cancer: a potent prognostic factor associated with intratumoral neutrophil infiltration. Breast Cancer. 2023 Sep;30(5):748-757.DOI: 10.1007/s12282-023-01467-0

  3. Ebata A, Suzuki S, Ishida T, et al. Immunolocalization of Cytoplasmic ER in ER-negative Breast Carcinoma as a Potent Favorable Prognostic Predictor. Acta Histochem Cytochem. 2023 Aug 30;56(4):59-66. doi: 10.1267/ahc.23-00016. 

  4. Junjia Zhang, Miki　Y, Iwabuchi E, et al. Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients. Breast Cancer Res Treat. 2023 Aug;200(3):323-335. doi: 10.1007/s10549-023-06990-4.

  5. Inoue C, Miki Y, Suzuki T. New Perspectives on Sex Steroid Hormones Signaling in Cancer-Associated Fibroblasts of Non-Small Cell Lung Cancer. Cancers (Basel). 2023 Jul 14;15(14):3620. doi: 10.3390/cancers15143620.

  6. Sato A, Takagi K, Yoshimura A, et al. Kallikrein-Related Peptidase 12 (KLK12) in Breast Cancer as a Favorable Prognostic Marker. Int J Mol Sci. 2023 May 8;24(9):8419. DOI: 10.3390/ijms24098419

  7. Watanabe H, Fujishima F, Unno M, et al. Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells. Pathol Res Pract. 2023 Apr;244:154418.

  8. Yamaguchi-Tanaka M, Takagi K, Miki Y, et al. The Pro-Tumorigenic Role of Chemotherapy-Induced Extracellular HSP70 from Breast Cancer Cells via Intratumoral Macrophages.Cancers (Basel). 2023 Mar 22;15(6):1903. DOI: 10.3390/cancers15061903

  9. Yamamoto T, Kimura T, Kubo Y, et al. An adrenal incidentaloma that had appeared to produce dehydroepiandrosterone-sulfate in excess before immunohistochemical study of the tumor. Endocr J. 2023 Jan 30;70(1):43-6.

  10. Inoue C, Ohkouchi S, Chonan T, et al. A case report of Indium lung with progressive emphysema and fibrosis underwent lung unilateral transplantation 20 years after the end of the exposure. Diagn Pathol. 2023 Jan 28;18(1):10. 

  11. Miki　Y, Iwabuchi E, Suzuki T. In Situ Proximity Ligation Assay to Visualize Protein-Protein Interactions in Tumor Specimens. Methods Mol Biol. 2023;2660:123-35. 

  12. Numasaki M, Ito K, Takagi K, et al.Diverse and divergent functions of IL-32β and IL-32γ isoforms in the regulation of malignant pleural mesothelioma cell growth and the production of VEGF-A and CXCL8. Cell Immunol. 2023 Jan;383:104652 

2022

  1. Horie K, Takagi K, Takeiwa T, et al. Estrogen-Inducible LncRNA BNAT1 Functions as a Modulator for Estrogen Receptor Signaling in Endocrine-Resistant Breast Cancer Cells. Cells. 2022 Nov 15;11(22):3610. 

  2. Shimada H, Hata S, Nakamura Y, et al. YM750, an ACAT Inhibitor, Acts on Adrenocortical Cells to Inhibit Aldosterone Secretion Due to Depolarization. Int J Mol Sci. 2022 Oct 24;23(21):12803.

  3. Sato N, Motoi F, Unno M, et al. Expression of corticotropin-releasing hormone and its receptors may be associated with survival rate in pancreatic cancer.Gastro Hep Advances. September 15, 2022

  4. Nishimura T, Takadate T, Maeda S, et al. Disease-related protein co-expression networks are associated with the prognosis of resectable node-positive pancreatic ductal adenocarcinoma. Sci Rep. 2022 Aug 29;12(1):14709.

  5. Junyao Xu, Iwabuchi E, Sasano H, et al. FE65 defines the efficacy of tamoxifen treatment via osteopontin expression in estrogen receptor-positive breast cancer. Pathol Res Pract. 2022 Jun;234:153898.  

  6. Miki　Y, Iwabuchi E, Takagi K, et al. Co-expression of nuclear heterogeneous nuclear ribonucleic protein K and estrogen receptor α in endometrial cancer. Pathol Res Pract. 2022 Mar;231:153795.

  7. Sato T, Takagi K, Suzuki T, et al. Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. Acta Histochem Cytochem. 2022 Feb 26;55(1):25-35. DOI: 10.1267/ahc.21-00075

  8. Freeha Khalid, Takagi K, Suzuki T, et al. IL-17A is a poor prognostic factor and recruits chemokines in triple negative breast cancer. cancer science. 2022;113: 1029-1029

  9. Iwabuchi E, Miki Y, Suzuki T, et al. Visualization of the protein-protein interactions of hormone receptors in hormone-dependent cancer research. Endocr Oncol. 2022 Oct 3;2(1):R132-R142. doi: 10.1530/EO-22-0059.

  10. Takagi K, Yamaguchi M, Suzuki T, et al. Diverse role of androgen action in human breast cancer.
    Endocr Oncol. 2022 Aug 22;2(1):R102-R111. doi: 10.1530/EO-22-0048. eCollection 2022 Jan.

  11. Yamaguchi M, Sasaki T, Suzuki T, et al. Automatic breast carcinoma detection in　histopathological micrographs based on Single Shot Multibox Detector. J Pathol Inform. 2022 Sep 26;13:100147. DOI: 10.1016/j.jpi.2022.100147

2021

  1. Yokoyama A, Kouketsu T, Otsubo Y, et al. Identification and Functional Characterization of a Novel Androgen Receptor Coregulator, EAP1. J Endocr Soc. 2021 Sep 13;5(11):bvab150. 

  2. Hayashi C, Takagi K, Sato A, Suzuki T, et al. D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation. Histol Histopathol. 2021 Oct;36(10):1053-62. DOI: 10.14670/HH-18-362

  3. Hirashima T, Karasawa H, Aizawa T, et al. Wnt5a in cancer-associated fibroblasts promotes colorectal cancer progression. Biochem Biophys Res Commun. 2021 Sep 3;568:37-42.

  4. Yamaguchi M, Takagi K, Sato M, et al. Androgens enhance the ability of intratumoral macrophages to promote breast cancer progression. Oncol Rep. 2021 Sep;46(3):188. DOI: 10.3892/or.2021.8139

  5. Azuma K, Suzuki T, Inoue S, et al. TRIM47 activates NF-κB signaling via PKC-ε/PKD3 stabilization and contributes to endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A. 2021 Aug 31;118(35):e2100784118.

  6. Shindo H, Harada-Shoji N, Ebata A, et al. Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast Cancer. Cancers (Basel). 2021 Aug 30;13(17):4375.

  7. Onodera Y, Takagi K, Neoi Y, Suzuki T, et al. Forkhead Box I1 in Breast Carcinoma as a Potent Prognostic Factor. Acta Histochem Cytochem. 2021 Aug 25;54(4):123-130. DOI: 10.1267/ahc.21-00034

  8. Takayama K, Suzuki T, Inoue S, et al. Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth. Cancer Res. 2021 Jul 1;81(13):3495-508.

  9. Minemura H, Takagi K, Sato A, Yamagushi M, Hayashi C, Suzuki T, et al. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases. Breast Cancer. 2021 Jul;28(4):915-26. DOI: 10.1007/s12282-021-01228-x

  10. Takayama K, Suzuki T, Inoue S, et al. Subtype-specific collaborative transcription factor networks are promoted by OCT4 in the progression of prostate cancer. Nat Commun. 2021 Jun 18;12(1):3766.

  11. Kamada S, Suzuki T, Inoue S, et al. Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma. Oncogene. 2021 Jun;40(22):3899-913.

  12. Xin Gao, Yamazaki Y, Suzuki T, Sasano H, et al. Pathology of Aldosterone Biosynthesis and its Action. Tohoku J Exp Med. 2021 May;254(1):1-15.

  13. Iwabuchi E, Suzuki T, Sasano H, et al. Heterogeneous Nuclear Ribonucleoprotein K Is Involved in the Estrogen-Signaling Pathway in Breast Cancer. Int J Mol Sci. 2021 Mar 4;22(5):2581. DOI: 10.3390/ijms22052581

  14. Yamaguchi M, Takagi K, Narita K, et al. Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells. Int J Mol Sci. 2021 Feb 15;22(4):1918. DOI: 10.3390/ijms22041918

  15. Okazaki K, Suzuki T, Sekine H, et al. Publisher Correction: Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers. Nat Commun. 2021 Jan 15;12(1):506.

  16. Sato M, Harada-Shoji N, Suzuki T, et al. L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism. Sci Rep. 2021 Jan 12;11(1):589. 

  17. Kamada S, Suzuki T, Inoue S, et al. Clinicopathological and Preclinical Patient-Derived Model Studies Define High Expression of NRN1 as a Diagnostic and Therapeutic Target for Clear Cell Renal Cell Carcinoma. Front Oncol. 2021 Nov 3;11:758503. 

2020

  1. Okazaki K, Sekine H, Motohashi H, et al. Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers. Nat Commun. 2020 Nov 20;11(1):5911.

  2. Namekawa T, Kitayama S, Inoue S, et al. HIF1α inhibitor 2-methoxyestradiol decreases NRN1 expression and represses in vivo and in vitro growth of patient-derived testicular germ cell tumor spheroids. Cancer Lett. 2020 Oct 1;489:79-86.

  3. Yamaguchi M, Takagi K, Sato A, et al. Rac1 activation in human breast carcinoma as a prognostic factor associated with therapeutic resistance. Breast Cancer. 2020 Sep;27(5):919-28. DOI: 10.1007/s12282-020-01091-2

  4. Mitobe Y, Iino K, Inoue S, et al. PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of ESR1 and SCFD2. Cancer Res. 2020 Jun 1;80(11):2230-42.

  5. Sato J, Karasawa H, Suzuki T, et al. The Function and Prognostic Significance of Cripto-1 in Colorectal Cancer. Cancer Invest. 2020 Apr;38(4):214-27.

  6. Yamada Y, Kimura N, Inoue S, et al. TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma. Cancer Sci. 2020 Mar;111(3):881-90.

  7. Suzuki Y, Takadate T, Mizuma M, et al. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. PloS one. 2020 Jul 14;15(7)

  8. Iino K, Mitobe Y, Inoue S, et al. RNA-binding protein NONO promotes breast cancer proliferation by post-transcriptional regulation of SKP2 and E2F8. Cancer Sci. 2020 Jan;111(1):148-59.

  9. Hoshi Y, Uchida Y, Kuroda T, et al. Distinct roles of ezrin, radixin and moesin in maintaining the plasma membrane localizations and functions of human blood-brain barrier transporters. J Cereb Blood Flow Metab 2020;40(7): 1533-45.

  10. Namekawa T, Ikeda K, Inoue S, et al. ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression. Int J Cancer 2020;146(4): 1099-113.

  11. Hoshi Y, Uchida Y, Terasaki T, et al. Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood-brain barrier. J Cereb Blood Flow Metab 2020;40(2): 420-36.

2019

  1. Mitobe Y, Suzuki T, Inoue S, et al. ESR1-Stabilizing Long Noncoding RNA TMPO-AS1 Promotes Hormone-Refractory Breast Cancer Progression. Mol Cell Biol. 2019 Nov 12;39(23) .

  2. Harada-Shoji N, Soga T, Tada H, et al. A metabolic profile of routine needle biopsies identified tumor type specific metabolic signatures for breast cancer stratification: a pilot study. Metabolomics 2019 Nov 4;15(11):147.

  3. Iwabuchi E, Miki Y, Sasano H, et al. Co-expression of carcinoembryonic antigen-related cell adhesion molecule 6 and 8 inhibits proliferation and invasiveness of breast carcinoma cells. Clin Exp Metastasis 2019; 36: 423-32. DOI: 10.1007/s10585-019-09981-2

  4. Aizawa T, Karasawa H, Funayama R, et al. Cancer-associated fibroblasts secrete Wnt2 to promote cancer progression in colorectal cancer. Cancer Med 2019; 8(14): 6370-82.

  5. Sato A, Takagi K, Suzuki T, et al. Cytochrome c1 as a favorable prognostic marker in estrogen receptor-positive breast carcinoma. Histol Histopathol 2019; 34(12): 1365-75. DOI: 10.14670/HH-18-130

  6. Kikuchi K, Saigusa D, Abe T, et al. Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun 2019; 10: 1835.

  7. Takenami T, Maeda S, Karasawa H, et al. Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis. BMC Cancer 2019; 19: 318.

2018

  1. Iwabuchi E, Miki Y, Sasano H, et al. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer. J Pathol 2018; 246: 379-89. DOI: 10.1002/path.5148

  2. Mayama A, Takagi K, Suzuki T, et al. OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma. Cancer Sci 2018; 109: 3350-9. DOI: 10.1111/cas.13770

  3. Fue M, Miki Y, Takagi K, et al. Relaxin 2/RXFP1 Signaling Induces Cell Invasion via the beta-Catenin Pathway in Endometrial Cancer. Int J Mol Sci 2018 Aug 18;19(8):2438. DOI: 10.3390/ijms19082438

  4. Uchida Y, Sumiya T, Tachikawa M, et al. Involvement of Claudin-11 in Disruption of Blood-Brain, -Spinal Cord, and -Arachnoid Barriers in Multiple Sclerosis. Mol Neurobiol 2019 Mar;56(3):2039-56.

  5. Shimura M, Mizuma M, Takadate T, et al. A novel liver metastasis-correlated protein of pancreatic neuroendocrine neoplasm (PanNEN) discovered by proteomic analysis. Oncotarget 2018; 9: 24291-303.

  6. Takayama KI, Suzuki T, Inoue S, et al. COBLL1 modulates cell morphology and facilitates androgen receptor genomic binding in advanced prostate cancer. Proc Natl Acad Sci U S A 2018; 115: 4975-80.

  7. Takagi K, Miki Y, Ishida T, et al. The interplay of endocrine therapy, steroid pathways and therapeutic resistance:  Importance of androgen in breast carcinoma. Mol Cell Endocrinol 2018; 466: 31-7. DOI: 10.1016/j.mce.2017.09.011

  8. Takayama KI, Suzuki T, Inoue S, et al. Association of USP10 with G3BP2 Inhibits p53 Signaling and Contributes to Poor Outcome in Prostate Cancer. Mol Cancer Res 2018; 16: 846-56.

  9. Hashimoto C, Miki Y, Ito K, et al. 17beta-Hydroxysteroid Dehydrogenase Type 2 Expression Is Induced by Androgen Signaling in Endometrial Cancer. Int J Mol Sci 2018 Apr 10;19(4):1139.

  10. Takayama KI, Suzuki T, Inoue S, et al. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. Oncogene 2018; 37: 2165-80.

  11. Takagi K, Miki Y, Onodera Y, et al. ARHGAP15 in Human Breast Carcinoma: A Potent Tumor Suppressor Regulated by Androgens. Int J Mol Sci 2018 Mar 10;19(3):804. DOI: 10.3390/ijms19030804

2017

  1. Kitamura H, Onodera Y, Motohashi H, et al. IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model. Oncogene 2017; 36: 6315-24.

  2. Miki Y, Hata S, Ono K, et al. Roles of Aryl Hydrocarbon Receptor in Aromatase-Dependent Cell Proliferation in Human Osteoblasts. Int J Mol Sci 2017 Oct 17;18(10):2159.

  3. Takayama KI, Suzuki T, Inoue S, et al. Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proc Natl Acad Sci U S A 2017; 114: 10461-6.

  4. Chishiki M, Takagi K, Suzuki T, et al. Cytochrome c1 in ductal carcinoma in situ of breast associated with proliferation and comedo necrosis. Cancer Sci 2017; 108: 1510-9. DOI: 10.1111/cas.13251

  5. Sakurai M, Miki Y, Sasano H, et al. Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment. Breast Cancer Res 2017; 19: 70.

  6. Nakayama S, Karasawa H, Suzuki T, et al. p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Med 2017; 6: 1264-74. DOI: 10.1002/cam4.1093

  7. Tsuji K, Utsunomiya H, Miki Y, et al. Retinoic Acid Receptor beta: A Potential Therapeutic Target in Retinoic Acid Treatment of Endometrial Cancer. Int J Gynecol Cancer 2017; 27: 643-50.

  8. Katagiri M, Karasawa H, Suzuki T, et al. Hexokinase 2 in colorectal cancer: a potent prognostic factor associated with glycolysis, proliferation and migration. Histol Histopathol 2017; 32: 351-60. DOI: 10.14670/HH-11-799

  9. Kakugawa Y, Tada H, Minami Y, et al. Associations of obesity and physical activity with serum and intratumoral sex steroid hormone levels among postmenopausal women with breast cancer: analysis of paired serum and tumor tissue samples. Breast Cancer Res Treat 2017; 162: 115-25.

  10. Saito R, Miki Y, Hata S, et al. Aryl hydrocarbon receptor induced intratumoral aromatase in breast cancer. Breast Cancer Res Treat 2017; 161: 399-407.

  11. Iwabuchi E, Miki Y, Sasano H, et al. In situ detection of estrogen receptor dimers in breast carcinoma cells in archival materials using proximity ligation assay (PLA). J Steroid Biochem Mol Biol 2017; 165: 159-69.

2016

  1. Obinata D, Takayama K, Inoue S, et al. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth. Oncogene 2016; 35: 6350-8.

  2. Minemura H, Takagi K, Suzuki T, et al. CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance. Cancer Sci 2016; 107: 1898-908. DOI: 10.1111/cas.13081

  3. Ohba K, Takeda K, Shibahara S, et al. Microphthalmia-associated transcription factor ensures the elongation of axons and dendrites in the mouse frontal cortex. Genes Cells 2016; 21: 1365-79.

  4. Shibahara Y, Sugawara Y, Miki Y, et al. Analysis of multiple primary cancer autopsy cases associated with breast cancer:  2002-2010. Pathol Int 2016; 66: 695-700.

  5. Hasegawa K, Tagawa M, Numasaki M, et al. Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-lambda2 or IL-29/IFN-lambda1. Cancer Gene Ther 2016; 23: 266-77.

  6. Onodera Y, Takagi K, Suzuki T, et al. TACC2 (transforming acidic coiled-coil protein 2) in breast carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Med 2016; 5: 1973-82. DOI: 10.1002/cam4.736

  7. Ito K, Miki Y, Suzuki T, et al. In situ androgen and estrogen biosynthesis in endometrial cancer: focus on androgen actions and intratumoral production. Endocr Relat Cancer 2016; 23: R323-35.

  8. Miki Y, Hata S, Nagasaki S, et al. Steroid and xenobiotic receptor-mediated effects of bisphenol A on human osteoblasts. Life Sci 2016; 155: 29-35.

  9. Hanamura T, Ito T, Ito K, et al. Human 3beta-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations. Cancer Med 2016 Jul;5(7):1405-15.

  10. Ishida K, Sasano H, Moriya T, et al. Immunohistochemical analysis of steroidogenic enzymes in ovarian-type stroma of pancreatic mucinous cystic neoplasms: Comparative study of subepithelial stromal cells in intraductal papillary mucinous neoplasms of the pancreas. Pathol Int 2016; 66: 281-7.

  11. Takagi K, Miki Y, Tanaka S, et al. Nucleobindin 2 (NUCB2) in human endometrial carcinoma: a potent prognostic factor associated with cell proliferation and migration. Endocr J 2016; 63: 287-99. DOI: 10.1507/endocrj.EJ15-0490

  12. Takagi M, Miki Y, Miyashita M, et al. Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas. Breast Cancer Res Treat 2016; 156: 45-55.

  13. Nakagawa S, Miki Y, Sasano H, et al. Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Res Treat 2016; 155: 65-75.

  14. Nakajima Y, Osakabe A, Waku T, et al. Estrogen Exhibits a Biphasic Effect on Prostate Tumor Growth through the Estrogen Receptor beta-KLF5 Pathway. Mol Cell Biol 2016; 36: 144-56.

2015

  1. Takayama K, Misawa A, Inoue S, et al. Corrigendum: TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun 2015; 6: 10265.

  2. Minemura H, Takagi K, Suzuki T, et al. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor. Cancer Sci 2015; 106: 1642-50. DOI: 10.1111/cas.12808

  3. Takagi K, Miki Y, Nakamura Y, et al. Immunolocalization of thymidylate synthase as a favorable prognostic marker in estrogen receptor-positive breast carcinoma. Histol Histopathol 2015; 30: 1223-32. DOI: 10.14670/HH-11-619

  4. Takayama K, Misawa A, Inoue S, et al. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun 2015; 6: 8219.

  5. Yoda T, Kikuchi K, McNamara KM, et al. 11beta-Prostaglandin F2alpha, a bioactive metabolite catalyzed by AKR1C3, stimulates prostaglandin F receptor and induces slug expression in breast cancer. Mol Cell Endocrinol 2015; 413: 236-47.

  6. Maeda S, Morikawa T, Unno M, et al. Mass spectrometry-based proteomic analysis of formalin-fixed paraffin-embedded extrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2015; 22: 683-91.

  7. Uchida Y, Ito K, Terasaki T, et al. Major involvement of Na(+) -dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells. J Neurochem 2015; 134: 97-112.

  8. Yoda T, McNamara KM, Miki Y, et al. KLF15 in breast cancer: a novel tumor suppressor? Cell Oncol (Dordr) 2015; 38: 227-35.

  9. Murakami M, Suzuki T, Wu TW, et al. Modified autonomic regulation in mice mutated in the beta4 subunit of the lh/lh calcium channel. Biochem Biophys Res Commun 2015; 461: 200-5.

  10. McNamara KM, Yoda T, Miki Y, et al. Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triple-negative breast cancer. Int J Biol Markers 2015; 30: e184-9.

  11. Narumi S, Miki Y, Sasano H, et al. Anterior gradient 2 is correlated with EGFR mutation in lung adenocarcinoma tissues. Int J Biol Markers 2015; 30: e234-42.

  12. Sakurai M, Masuda M, Sasano H, et al. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients. Int J Biol Markers 2015; 30: e190-9.

  13. Takayama K, Suzuki T, Inoue S, et al. RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer. Oncotarget 2015; 6: 2263-76.

  14. Watanabe K, Okumura Y, Hashimoto K, et al. Clear cell carcinoma of the base of the tongue: case report and literature review. Ann Otol Rhinol Laryngol 2015; 124: 55-61.

  15. Ujihira T, Ikeda K, Inoue S, et al. MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer. Sci Rep 2015; 5: 7641.

  16. Ikeda K, Horie-Inoue K, Inoue S, et al. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A. Sci Rep 2015; 5: 13170.

2014

  1. Tanaka S, Miki Y, Hashimoto C, et al. The role of 5alpha-reductase type 1 associated with intratumoral dihydrotestosterone concentrations in human endometrial carcinoma. Mol Cell Endocrinol 2014; 401C: 56-64.

  2. Takayama K, Suzuki T, Inoue S, et al. Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol 2014; 28: 2012-24.

  3. Takayama K, Suzuki T, Inoue S, et al. CtBP2 modulates the androgen receptor to promote prostate cancer progression. Cancer Res 2014; 74: 6542-53.

  4. Yoda T, McNamara KM, Miki Y, et al. Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. Cancer Sci 2014; 105: 1503-9.

  5. Sato N, Takagi K, Ito K, et al. Immunolocalization of corticotropin-releasing hormone (CRH) and its receptors (CRHR1 and CRHR2) in human endometrial carcinoma: CRHR1 as a potent prognostic factor. Int J Gynecol Cancer 2014; 24: 1549-57.

  6. Fujii R, Hanamura T, Hayashi S, et al. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid Biochem Mol Biol 2014; 144 Pt B: 513-22.

  7. Nishihara H, Suzuki T, Itoi H, et al. Conversion of silica nanoparticles into Si nanocrystals through electrochemical reduction. Nanoscale 2014; 6: 10574-83.

  8. Taniuchi S, Fujishima F, Suzuki T, et al. Tissue concentrations of estrogens and aromatase immunolocalization in interstitial pneumonia of human lung. Mol Cell Endocrinol 2014; 392: 136-43. DOI: 10.1016/j.mce.2014.05.016

  9. McNamara KM, Yoda T, Nurani AM, et al. Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes. Breast Cancer Res Treat 2014; 145: 281-93.

  10. Takagi K, Moriguchi T, Miki Y, et al. GATA4 immunolocalization in breast carcinoma as a potent prognostic predictor. Cancer Sci 2014; 105: 600-7. DOI: 10.1111/cas.12382

  11. Nihira K, Miki Y, Sasano H, et al. An inhibition of p62/SQSTM1 caused autophagic cell death of several human carcinoma cells. Cancer Sci 2014; 105: 568-75.

  12. Iida S, Miki Y, Sasano H, et al. Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma. Anticancer Res 2014; 34: 1821-7.

  13. Onodera Y, Motohashi H, Suzuki T, et al. NRF2 immunolocalization in human breast cancer patients as a prognostic factor. Endocr Relat Cancer 2014; 21: 241-52. DOI: 10.1530/ERC-13-0234

  14. Saito R, Miki Y, Hata S, et al. Aryl hydrocarbon receptor in breast cancer-a newly defined prognostic marker. Horm Cancer 2014; 5: 11-21.

  15. Ohba K, Suzuki T, Takahashi K, et al. Expression of (pro)renin receptor in breast cancers and its effect on cancercell proliferation. Biomed Res 2014; 35: 117-26.

  16. Kubo H, Suzuki T, Matsushima T, et al. Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer. BMC Cancer 2014; 14: 755.

2013

  1. Nakano K, Miki Y, Sasano H, et al. Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer. Anticancer Res 2013; 33: 4811-9.

  2. Takagi K, Ito S, Miyazaki T, et al. Amyloid precursor protein in human breast cancer: an androgen-induced gene associated with cell proliferation. Cancer Sci 2013; 104: 1532-8. DOI: 10.1111/cas.12239

  3. Sato-Tadano A, Suzuki T, Amari M, et al. Hexokinase II in breast carcinoma: A potent prognostic factor associated with hypoxia-inducible factor-1alpha and Ki-67. Cancer Sci 2013; 104: 1380-8. DOI: 10.1111/cas.12238

  4. Shibahara Y, Miki Y, Sakurada C, et al. Androgen and androgen-metabolizing enzymes in metastasized lymph nodes of breast cancer. Hum Pathol 2013; 44: 2338-45.

  5. Yazdani S, Miki Y, Sasano H, et al. Proliferation and maturation of intratumoral blood vessels in non-small cell lung cancer. Hum Pathol 2013; 44: 1586-96.

  6. Takagi K, Ishida T, Suzuki T, et al. Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment. Br J Cancer 2013; 109: 100-8. DOI: 10.1038/bjc.2013.284

  7. Takayama K, Horie-Inoue K, Inoue S, et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J 2013; 32: 1665-80.

  8. McNamara KM, Yoda T, Miki Y, et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci 2013; 104: 639-46.

  9. Nakamura Y, Felizola SJ, Kurotaki Y, et al. Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERbeta) in human prostate cancer. Prostate 2013; 73: 590-5.

  10. Iida S, Kakinuma H, Sasano H, et al. Steroid sulphatase and oestrogen sulphotransferase in human non-small-cell lung carcinoma. Br J Cancer 2013; 108: 1415-24.

  11. Takagi K, Miki Y, Suzuki T, et al. BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients. Horm Cancer 2013; 4: 92-102. DOI: 10.1007/s12672-012-0130-x

  12. Takadate T, Onogawa T, Fukuda T, et al. Novel prognostic protein markers of resectable pancreatic cancer identified by coupled shotgun and targeted proteomics using formalin-fixed paraffin-embedded tissues. Int J Cancer 2013; 132: 1368-82.

  13. Takagi K, Moriya T, Kurosumi M, et al. Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma. Horm Cancer 2013; 4: 1-11. DOI: 10.1007/s12672-012-0126-6

  14. Chan M, Wang L, Chanplakorn N, et al. Author's response. Expert Opin Ther Targets 2013; 17: 106.

  15. McNamara KM, Yoda T, Takagi K, et al. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 2013; 133: 66-76.

  16. Shibahara Y, Miki Y, Ishida T, et al. Immunohistochemical analysis of aromatase in metastatic lymph nodes of breast cancer. Pathol Int 2013; 63: 20-8.

  17. Verma MK, Miki Y, Sasano H, et al. Intratumoral localization and activity of 17beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor. J Transl Med 2013; 11: 167.

  18. Yamada M, Kubo H, Ota C, et al. The increase of microRNA-21 during lung fibrosis and its contribution to epithelial-mesenchymal transition in pulmonary epithelial cells. Respir Res 2013; 14: 95.

2012

  1. Sase T, Suzuki T, Sasano H, et al. Runt-related transcription factor 2 in human colon carcinoma: a potent prognostic factor associated with estrogen receptor. Int J Cancer 2012; 131: 2284-93.

  2. Kobayashi M, Miki Y, Sasano H, et al. Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. Br J Cancer 2012; 107: 1745-53.

  3. Chan MS, Wang L, Sasano H, et al. Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an immunohistochemical study of Cd8+ and Foxp3+ using double immunostaining with correlation to the pathobiological response of the patients. Int J Biol Markers 2012; 27: e295-304.

  4. Masuda M, Miki Y, Sasano H, et al. An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. J Transl Med 2012; 10 Suppl 1: S2.

  5. Miki Y, Ono K, Hata S, et al. The advantages of co-culture over mono cell culture in simulating in vivo environment. J Steroid Biochem Mol Biol 2012; 131: 68-75.

  6. Sakurai M, Miki Y, Sasano H, et al. LIN28: a regulator of tumor-suppressing activity of let-7 microRNA in human breast cancer. J Steroid Biochem Mol Biol 2012; 131: 101-6.

  7. Hiroki E, Suzuki F, Akahira J, et al. MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma. Int J Cancer 2012; 131: E395-404.

  8. Sato R, Suzuki T, Sasano H, et al. Aromatase in colon carcinoma. Anticancer Res 2012; 32: 3069-75.

  9. Ebata A, Suzuki T, Sasano H, et al. Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. Endocr Relat Cancer 2012; 19: 485-96.

  10. Shibahara Y, Miki Y, Sasano H, et al. Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol 2012; 227: 357-66.

  11. Takayama K, Horie-Inoue K, Inoue S, et al. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated  and castration-resistant growth of prostate cancer. Mol Endocrinol 2012; 26: 748-61.

  12. Fujino N, Kubo H, Ota C, et al. A novel method for isolating individual cellular components from the adult human distal lung. Am J Respir Cell Mol Biol 2012; 46: 422-30.

  13. Inoue D, Motohashi H, Yamamoto M, et al. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci 2012; 103: 760-6.

  14. Iida S, Miki Y, Sasano H, et al. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor. Mol Cell Endocrinol 2012; 350: 99-106.

  15. Chan MS, Wang L, Chanplakorn N, et al. Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma--an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy. Expert Opin Ther Targets 2012; 16 Suppl 1: S69-78.

  16. Suzuki S, Takagi K, Miki Y, et al. Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. Cancer Sci 2012; 103: 136-43. DOI: 10.1111/j.1349-7006.2011.02119.x

  17. Takadate T, Onogawa T, Fujii K, et al. Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue. Clin Proteomics 2012; 9: 8.

  18. Takagi K, Miki Y, Onodera Y, et al. Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocr Relat Cancer 2012; 19: 741-50. DOI: 10.1530/ERC-12-0017

  19. Nagasaki S, Nakamura Y, Maekawa T, et al. Immunohistochemical analysis of gastrin-releasing peptide receptor (GRPR) and possible regulation by estrogen receptor betacx in human prostate carcinoma. Neoplasma 2012; 59: 224-32.

2011

  1. Miki Y, Suzuki S, Sasano H, et al. Suppression of estrogen actions in human lung cancer. Mol Cell Endocrinol 2011; 340: 168-74.

  2. Suzuki T, Miki Y, Nakamura Y, et al. Steroid sulfatase and estrogen sulfotransferase in human carcinomas. Mol Cell Endocrinol 2011; 340: 148-53. DOI: 10.1016/j.mce.2010.11.001

  3. Fujishima F, Suzuki T, Nakamura Y, et al. Retinoid receptors in human esophageal squamous cell carcinoma: retinoid X receptor as a potent prognostic factor. Pathol Int 2011; 61: 401-8.

  4. Escobar JC, Suzuki T, B R Carr, et al. The human placenta expresses CYP17 and generates androgens de novo. J Clin Endocrinol Metab 2011; 96: 1385-92.

  5. Oka K, Suzuki T, Sasano H, et al. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation. Int J Cancer 2011; 128: 1770-82.

  6. Toi M, Saji S, Masuda N, et al. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci 2011; 102: 858-65.

  7. Nakajima Y, Suzuki T, Yanagisawa J, et al. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcription factors ERβ and KLF5. Sci Signal 2011; 4: ra22.

  8. Fujino N, Kubo H, Suzuki T, et al. Isolation of alveolar epithelial type II progenitor cells from adult human lungs. Lab Invest 2011; 91: 363-78.

  9. Inoue D, Motohashi H, Yamamoto M, et al. Inducible disruption of autophagy in the lung causes airway hyper-responsiveness. Biochem Biophys Res Commun 2011; 405: 13-8.

  10. Chanplakorn N, Suzuki T, Sasano H, et al. Increased 5alpha-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. Horm Cancer 2011; 2: 73-81.

  11. Morimoto R, Kudo M,  Satoh F, et al. Difficult-to-control hypertension due to bilateral aldosterone-producing adrenocortical microadenomas associated with a cortisol-producing adrenal macroadenoma. J Hum Hypertens 2011; 25: 114-21.

  12. Oyama M, Nagashima T, Satoh F, et al. Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer. J Biol Chem 2011; 286: 818-29.

  13. Kawakami H, Ohtsuki S, Terasaki T, et al. Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection. J Pharm Sci 2011; 100: 341-52.

2010

  1. Onodera Y, Suzuki T, Sasano H, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression. Cancer Sci 2010; 101: 2670-5.

  2. Sirianni R, Nogueira E, Rainey WE, et al. The AP-1 family member FOS blocks transcriptional activity of the nuclear receptor steroidogenic factor 1. J Cell Sci 2010; 15: 3956-65.

  3. Iida S, Miki Y, Sasano H, et al. Novel classification based on immunohistochemistry combined with hierarchical clustering analysis in non-functioning neuroendocrine tumor patients. Cancer Sci 2010; 101: 2278-85.

  4. Sasaki Y, Miki Y, Suzuki T, et al. Immunolocalization of estrogen-producing and metabolizing enzymes in benign breast disease: comparison with normal breast and breast carcinoma. Cancer Sci 2010; 101: 2286-92. DOI: 10.1111/j.1349-7006.2010.01673.x

  5. Miki Y, Suzuki T, Sasano H, et al. Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment. Cancer Res 2010; 70: 6659-69.

  6. Kisanuki YY, Suzuki T, Yanagisawa M, et al. Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 2010; 56: 121-8.

  7. Takagi K, Miki Y, Suzuki T, et al. Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr Relat Cancer 2010; 17: 415-30. DOI: 10.1677/ERC-09-0257

  8. Suzuki T, Miki Y, Takagi K, et al. Androgens in human breast carcinoma. Med Mol Morphol 2010; 43: 75-81. DOI: 10.1007/s00795-010-0494-3

  9. Ohta T, Suzuki T, Murakami M, et al. Decreased calcium channel currents and facilitated epinephrine release in the Ca2+ channel beta3 subunit-null mice. Biochem Biophys Res Commun 2010; 394: 464-9.

  10. Chanplakorn N, Suzuki T, Sasano H, et al. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 2010; 120: 639-48.

  11. Miyagawa K, Emoto N, Suzuki T, et al. Attenuation of Doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment. Hypertension 2010; 55: 738-46.

  12. Geisler J, Suzuki T, Helle H, et al. Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status. J Steroid Biochem Mol Biol 2010; 118: 237-41.

  13. Sasano H, Miki Y, Shibuya R, et al. Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast. J Steroid Biochem Mol Biol 2010; 118: 242-5.

  14. Takeyama D, Suzuki T, Sasano H, et al. Steroid and xenobiotic receptor in human esophageal squamous cell carcinoma: a potent prognostic factor. Cancer Sci 2010; 101: 543-9.

  15. Abe K, Miki Y, Ono K, et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol 2010; 41: 190-8.

  16. Hiroki E, Akahira J, Suzuki F, et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 2010; 101: 241-9.

  17. Widyantoro B, Emoto N, Nakayama K, et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010; 121: 2407-18.

2009

  1. Patel SS, Beshay VE, Escobar JC, et al. Molecular mechanism for repression of 17alpha-hydroxylase expression and androstenedione production in granulosa cells. J Clin Endocrinol Metab 2009; 94: 5163-8.

  2. Hui XG, Akahira J, Suzuki T, et al. Development of the human adrenal zona reticularis: morphometric and immunohistochemical studies from birth to adolescence. J Endocrinol 2009; 203: 241-52.

  3. Sasano H, Miki Y, Nagasaki S, et al. In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int 2009; 59: 777-89.

  4. Nagasaki S, Miki Y, Akahira J, et al. Transcriptional regulation of 17beta-hydroxysteroid dehydrogenase type 12 by SREBP-1. Mol Cell Endocrinol 2009; 307: 163-8.

  5. Loo WT, Chow LW, Suzuki T, et al. Expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in human breast carcinoma cells and tissues. Anticancer Res 2009; 29: 2525-30.

  6. Ellis MJ, Miller WR, Tao Y, et al. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res Treat 2009; 116: 371-8.

  7. Nakamura Y, Suzuki T, Sugawara A, et al. Peroxisome proliferator-activated receptor gamma in human prostate carcinoma. Pathol Int 2009; 59: 288-93.

  8. Nagasaki S, Suzuki T, Miki Y, et al. Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. Cancer Sci 2009; 100: 639-45.

  9. Miki Y, Suzuki T, Sasano H. Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. J Steroid Biochem Mol Biol 2009; 114: 68-71.

  10. Nakamura Y, Gang HX, Suzuki T, et al. Adrenal changes associated with adrenarche. Rev Endocr Metab Disord 2009; 10: 19-26.

  11. Nagasaki S, Suzuki T, Miki Y, et al. 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis. Cancer Res 2009; 69: 1392-9.

  12. Sato R, Suzuki T, Katayose Y, et al. Steroid sulfatase and estrogen sulfotransferase in colon carcinoma: regulators of intratumoral estrogen concentrations and potent prognostic factors. Cancer Res 2009; 69: 914-22.

  13. Sasano H, Nagasaki S, Miki Y, et al. New developments in intracrinology of human breast cancer: estrogen sulfatase and sulfotransferase. Ann N Y Acad Sci 2009; 1155: 76-9.

  14. Nagasaki S, Miki Y, Akahira J, et al. 17beta-hydroxysteroid dehydrogenases in human breast cancer. Ann N Y Acad Sci 2009; 1155: 25-32.

  15. Miki Y, Suzuki T, Nagasaki S, et al. Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene. J Steroid Biochem Mol Biol 2009; 113: 281-9.

  16. Takayama K, Tsutsumi S, Suzuki T, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 2009; 69: 137-42.

  17. Nakamura M, Miki Y, Akahira J, et al. An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocr Pathol 2009; 20: 17-23.

  18. Nakamura Y, Suzuki T, Arai Y, et al. Nuclear receptor DAX1 in human prostate cancer: a novel independent biological modulator. Endocr J 2009; 56: 39-44.

  19. Nakamura Y, Suzuki T, Arai Y, et al. 17beta-hydroxysteroid dehydrogenase type 11 (Pan1b) expression in human prostate cancer. Neoplasma 2009; 56: 317-20.

2008

  1. Suzuki F, Akahira J, Miura I, et al. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. Cancer Sci 2008; 99: 2365-72.

  2. Kaku U, Kameyama K, Izawa M, et al. Ovarian histological findings in an adult patient with the steroidogenic acute regulatory protein (StAR) deficiency reveal the impairment of steroidogenesis by lipoid deposition. Endocr J 2008; 55: 1043-9.

  3. Murakami M, Ohba T, Xu F, et al. Modified sympathetic nerve system activity with overexpression of the voltage-dependent calcium channel beta3 subunit. J Biol Chem 2008; 283: 24554-60.

  4. Morimoto R, Satoh F, Murakami O, et al. Expression of peptide YY in human brain and pituitary tissues. Nutrition 2008; 24: 878-84.

  5. Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008; 14: 4417-26.

  6. Suzuki T, Miki Y, Akahira J, et al. Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations. Endocr J 2008; 55: 455-63.

  7. Morimoto R, Satoh F, Murakami O, et al. Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues. J Endocrinol 2008; 198: 175-83.

  8. Matsumoto M, Yamaguchi Y, Seino Y, et al. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr Relat Cancer 2008; 15: 451-63.

  9. Morimoto R, Satoh F, Murakami O, et al. Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. Peptides 2008; 29: 873-80.

  10. Utsunomiya H, Cheng YH, Lin Z, et al. Upstream stimulatory factor-2 regulates steroidogenic factor-1 expression in endometriosis. Mol Endocrinol 2008; 22: 904-14.

  11. Dohi O, Hatori M, Suzuki T, et al. Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. Cancer Sci 2008; 99: 518-23.

  12. Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 2008; 55: 49-55.

  13. Shibuya R, Suzuki T, Miki Y, et al. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 2008; 15: 113-24.

  14. Tanabe K, Utsunomiya H, Tamura M, et al. Expression of retinoic acid receptors in human endometrial carcinoma. Cancer Sci 2008; 99: 267-71.

  15. Sasano H, Suzuki T, Miki Y, et al. Intracrinology of estrogens and androgens in breast carcinoma. J Steroid Biochem Mol Biol 2008; 108: 181-5.

  16. Sone M, Shoji I, Hiraishi K, et al. Immunohistochemistry of prolactin-releasing peptide and its receptor in adrenal tumors. 13th International congress of Endocrinology 2008; : 493-6.

  17. Suzuki T, Miki Y, Ohuchi N, et al. Intratumoral estrogen production in breast carcinoma: significance of aromatase. Breast Cancer 2008; 15: 270-7.

bottom of page